-
Wells Fargo Starts Celcuity Inc (CELC) at Overweight
-
Celcuity Inc (CELC) PT Raised to $134 at Jefferies
-
Jefferies on Celcuity Inc (CELC): 'we believe everolimus+gire could be a good option specifically for the PIK3CAwt/ESR1mut subgrp'
-
Increasing unusual call option volume: EQG CELC BBD FE CWAN
-
Wolfe Research Starts Celcuity Inc (CELC) at Outperform
-
H.C. Wainwright Downgrades Celcuity Inc (CELC) to Neutral
-
Celcuity Inc (CELC) PT Raised to $115 at Stifel
-
Celcuity (CELC) Tops Q3 EPS by 10c
-
Increasing unusual call option volume: BBD BORR APLS VIAV ROIV FMC VITL RSI METU OWL FBL FI CELC
-
Guggenheim Starts Celcuity Inc (CELC) at Buy
-
Celcuity increases term loan facility to $500 million
-
Celcuity Inc (CELC) PT Raised to $66 at H.C. Wainwright
-
Celcuity Inc (CELC) PT Raised to $68 at Stifel
-
Celcuity Inc (CELC) PT Lowered to $70 at Needham
-
Celcuity Inc (CELC) PT Raised to $79 at Jefferies
-
Celcuity (CELC) Misses Q2 EPS by 16c
-
Celcuity Inc (CELC) PT Raised to $50 at H.C. Wainwright
-
Celcuity receives patent extending gedatolisib exclusivity to 2042
-
Stifel Assumes Celcuity (CELC) at Buy
-
Celcuity (CELC) Reports Clinical Data from Two Early Phase Studies of Gedatolisib
-
Celcuity (CELC) Misses Q1 EPS by 14c
-
Stifel Reiterates Buy Rating on Celcuity Inc (CELC)
-
Celcuity (CELC) Misses Q4 EPS by 4c
-
Celcuity Inc (CELC) PT Raised to $33 at Jefferies
-
Celcuity (CELC) Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy
-
Celcuity (CELC) Reports In-Line Q3 EPS
-
Celcuity Inc (CELC) PT Raised to $42 at Stifel
-
TD Cowen Reiterates Buy Rating on Celcuity Inc (CELC)
-
Celcuity Inc (CELC) PT Lowered to $39 at Stifel
-
Celcuity (CELC) Tops Q2 EPS by 10c
-
Celcuity Inc (CELC) PT Lowered to $68 at Jefferies

